How chromatin remodeling affects cancer treatment and mechanisms
Official title: Oncogenic Chromatin Remodeling and Anticancer Mechanisms
Funded at Rutgers Biomedical and Health Sciences · NIH-11086144 · Data updated 2026-11-12
This study is looking at how a specific gene called ARID1A, which helps prevent tumors, is affected by a protein called mTORC1, and it hopes to find new ways to improve cancer treatments that target this pathway, which could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | June 8, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $453,067 |
| NIH project number | 5R01CA280177-03 |
| Project ID | NIH-11086144 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that have mutations in the ARID1A gene or those whose tumors show activation of the mTOR pathway.
✕Less likely to help
Patients with cancers unrelated to ARID1A mutations or those not involving the mTOR pathway may not benefit from this research.
What this research studies
This research investigates the role of chromatin remodeling in cancer, focusing on the ARID1A gene, which is crucial for tumor suppression. The study aims to understand how the mTORC1 protein kinase influences the degradation of ARID1A and its implications for cancer therapy. By exploring these mechanisms, the research seeks to uncover how cancer cells respond to treatments targeting the mTOR pathway, which is active in many tumors. Patients may benefit from insights that could lead to improved cancer therapies based on these findings.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by targeting the mechanisms that inactivate tumor suppressors.
How similar studies have gone: Previous research has shown promising results in targeting the mTOR pathway in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Zheng, Steven — Rutgers Biomedical and Health Sciences
- Study coordinator: Zheng, Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.